BIOMAT Database Logo BIOMAT Database Logo

Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy. 2012

Apar Pataer, and Neda Kalhor, and Arlene M Correa, and Maria Gabriela Raso, and Jeremy J Erasmus, and Edward S Kim, and Carmen Behrens, and J Jack Lee, and Jack A Roth, and David J Stewart, and Ara A Vaporciyan, and Ignacio I Wistuba, and Stephen G Swisher, and
Departments of Thoracic and Cardiovascular Surgery, the University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA. apataer@mdanderson.org

BACKGROUND We evaluated the ability of histopathologic response criteria to predict overall survival (OS) and disease-free survival (DFS) in patients with surgically resected non-small cell lung cancer (NSCLC) treated with or without neoadjuvant chemotherapy. METHODS Tissue specimens from 358 patients with NSCLC were evaluated by pathologists blinded to the patient treatment and outcome. The surgical specimens were reviewed for various histopathologic features in the tumor including percentage of residual viable tumor cells, necrosis, and fibrosis. The relationship between the histopathologic findings and OS was assessed. RESULTS The percentage of residual viable tumor cells and surgical pathologic stage were associated with OS and DFS in 192 patients with NSCLC receiving neoadjuvant chemotherapy in multivariate analysis (p = 0.005 and p = 0.01, respectively). There was no association of OS or DFS with percentage of viable tumor cells in 166 patients with NSCLC who did not receive neoadjuvant chemotherapy (p = 0.31 and p = 0.45, respectively). Long-term OS and DFS were significantly prolonged in patients who had ≤10% viable tumor compared with patients with >10% viable tumor cells (5 years OS, 85% versus 40%, p < 0.0001 and 5 years DFS, 78% versus 35%, p < 0.001). CONCLUSIONS The percentages of residual viable tumor cells predict OS and DFS in patients with resected NSCLC after neoadjuvant chemotherapy even when controlled for pathologic stage. Histopathologic assessment of resected specimens after neoadjuvant chemotherapy could potentially have a role in addition to pathologic stage in assessing prognosis, chemotherapy response, and the need for additional adjuvant therapies.

UI MeSH Term Description Entries
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D002289 Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy. Carcinoma, Non-Small Cell Lung,Non-Small Cell Lung Cancer,Non-Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinoma,Nonsmall Cell Lung Cancer,Carcinoma, Non Small Cell Lung,Carcinomas, Non-Small-Cell Lung,Lung Carcinoma, Non-Small-Cell,Lung Carcinomas, Non-Small-Cell,Non Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinomas
D002294 Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed) Carcinoma, Epidermoid,Carcinoma, Planocellular,Carcinoma, Squamous,Squamous Cell Carcinoma,Carcinomas, Epidermoid,Carcinomas, Planocellular,Carcinomas, Squamous,Carcinomas, Squamous Cell,Epidermoid Carcinoma,Epidermoid Carcinomas,Planocellular Carcinoma,Planocellular Carcinomas,Squamous Carcinoma,Squamous Carcinomas,Squamous Cell Carcinomas
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D003430 Cross-Sectional Studies Studies in which the presence or absence of disease or other health-related variables are determined in each member of the study population or in a representative sample at one particular time. This contrasts with LONGITUDINAL STUDIES which are followed over a period of time. Disease Frequency Surveys,Prevalence Studies,Analysis, Cross-Sectional,Cross Sectional Analysis,Cross-Sectional Survey,Surveys, Disease Frequency,Analyses, Cross Sectional,Analyses, Cross-Sectional,Analysis, Cross Sectional,Cross Sectional Analyses,Cross Sectional Studies,Cross Sectional Survey,Cross-Sectional Analyses,Cross-Sectional Analysis,Cross-Sectional Study,Cross-Sectional Surveys,Disease Frequency Survey,Prevalence Study,Studies, Cross-Sectional,Studies, Prevalence,Study, Cross-Sectional,Study, Prevalence,Survey, Cross-Sectional,Survey, Disease Frequency,Surveys, Cross-Sectional

Related Publications

Apar Pataer, and Neda Kalhor, and Arlene M Correa, and Maria Gabriela Raso, and Jeremy J Erasmus, and Edward S Kim, and Carmen Behrens, and J Jack Lee, and Jack A Roth, and David J Stewart, and Ara A Vaporciyan, and Ignacio I Wistuba, and Stephen G Swisher, and
Does graded histologic response after neoadjuvant chemotherapy predict survival for completely resected gastric cancer?
December 2007, Annals of surgical oncology,
Apar Pataer, and Neda Kalhor, and Arlene M Correa, and Maria Gabriela Raso, and Jeremy J Erasmus, and Edward S Kim, and Carmen Behrens, and J Jack Lee, and Jack A Roth, and David J Stewart, and Ara A Vaporciyan, and Ignacio I Wistuba, and Stephen G Swisher, and
Major pathologic response and RAD51 predict survival in lung cancer patients receiving neoadjuvant chemotherapy.
June 2018, Cancer medicine,
Apar Pataer, and Neda Kalhor, and Arlene M Correa, and Maria Gabriela Raso, and Jeremy J Erasmus, and Edward S Kim, and Carmen Behrens, and J Jack Lee, and Jack A Roth, and David J Stewart, and Ara A Vaporciyan, and Ignacio I Wistuba, and Stephen G Swisher, and
Major Pathologic Response and Prognostic Score Predict Survival in Patients With Lung Cancer Receiving Neoadjuvant Chemotherapy.
November 2022, JTO clinical and research reports,
Apar Pataer, and Neda Kalhor, and Arlene M Correa, and Maria Gabriela Raso, and Jeremy J Erasmus, and Edward S Kim, and Carmen Behrens, and J Jack Lee, and Jack A Roth, and David J Stewart, and Ara A Vaporciyan, and Ignacio I Wistuba, and Stephen G Swisher, and
Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy.
September 2009, Cancer,
Apar Pataer, and Neda Kalhor, and Arlene M Correa, and Maria Gabriela Raso, and Jeremy J Erasmus, and Edward S Kim, and Carmen Behrens, and J Jack Lee, and Jack A Roth, and David J Stewart, and Ara A Vaporciyan, and Ignacio I Wistuba, and Stephen G Swisher, and
Immune contexture and histological response after neoadjuvant chemotherapy predict clinical outcome of lung cancer patients.
January 2016, Oncoimmunology,
Apar Pataer, and Neda Kalhor, and Arlene M Correa, and Maria Gabriela Raso, and Jeremy J Erasmus, and Edward S Kim, and Carmen Behrens, and J Jack Lee, and Jack A Roth, and David J Stewart, and Ara A Vaporciyan, and Ignacio I Wistuba, and Stephen G Swisher, and
[Long survival case of resected lung cancer after chemotherapy with gefitinib].
August 2013, Kyobu geka. The Japanese journal of thoracic surgery,
Apar Pataer, and Neda Kalhor, and Arlene M Correa, and Maria Gabriela Raso, and Jeremy J Erasmus, and Edward S Kim, and Carmen Behrens, and J Jack Lee, and Jack A Roth, and David J Stewart, and Ara A Vaporciyan, and Ignacio I Wistuba, and Stephen G Swisher, and
Survival Analysis of Surgically Resected ypN2 Lung Cancer after Neoadjuvant Therapy.
April 2023, The Thoracic and cardiovascular surgeon,
Apar Pataer, and Neda Kalhor, and Arlene M Correa, and Maria Gabriela Raso, and Jeremy J Erasmus, and Edward S Kim, and Carmen Behrens, and J Jack Lee, and Jack A Roth, and David J Stewart, and Ara A Vaporciyan, and Ignacio I Wistuba, and Stephen G Swisher, and
Tumor blood supply may predict neoadjuvant chemotherapy response and survival in patients with gastric cancer.
June 2019, The Journal of international medical research,
Apar Pataer, and Neda Kalhor, and Arlene M Correa, and Maria Gabriela Raso, and Jeremy J Erasmus, and Edward S Kim, and Carmen Behrens, and J Jack Lee, and Jack A Roth, and David J Stewart, and Ara A Vaporciyan, and Ignacio I Wistuba, and Stephen G Swisher, and
Is major pathologic response sufficient to predict survival in resectable nonsmall-cell lung cancer patients receiving neoadjuvant chemotherapy?
May 2021, Thoracic cancer,
Apar Pataer, and Neda Kalhor, and Arlene M Correa, and Maria Gabriela Raso, and Jeremy J Erasmus, and Edward S Kim, and Carmen Behrens, and J Jack Lee, and Jack A Roth, and David J Stewart, and Ara A Vaporciyan, and Ignacio I Wistuba, and Stephen G Swisher, and
[Pathological complete response: A predictive survival factor after neoadjuvant chemotherapy in lung cancer].
January 2016, Bulletin du cancer,
Copied contents to your clipboard!